#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Discussion
1-1	0-2	3.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=While most nAChR agonists and antagonists binding at ACh orthosteric sites are basic molecules with at least one ionizable N , there are exceptions , including lophotoxin , the neonicotinoids and some recently synthesized pyrimidine agonists .
2-1	14-19	While	_	_	_	_
2-2	20-24	most	abstract[3]	new[3]	coref	2-32[13_3]
2-3	25-30	nAChR	abstract|abstract[3]	new|new[3]	coref	14-9
2-4	31-39	agonists	abstract[3]	new[3]	_	_
2-5	40-43	and	_	_	_	_
2-6	44-55	antagonists	object[4]	new[4]	coref	2-13[7_4]
2-7	56-63	binding	object[4]	new[4]	_	_
2-8	64-66	at	object[4]	new[4]	_	_
2-9	67-70	ACh	object[4]|abstract|place[6]	new[4]|new|new[6]	coref|coref	8-27|10-32[84_6]
2-10	71-82	orthosteric	object[4]|place[6]	new[4]|new[6]	_	_
2-11	83-88	sites	object[4]|place[6]	new[4]|new[6]	_	_
2-12	89-92	are	_	_	_	_
2-13	93-98	basic	object[7]	giv[7]	_	_
2-14	99-108	molecules	object[7]	giv[7]	_	_
2-15	109-113	with	object[7]	giv[7]	_	_
2-16	114-116	at	object[7]|abstract[8]	giv[7]|new[8]	_	_
2-17	117-122	least	object[7]|abstract[8]	giv[7]|new[8]	_	_
2-18	123-126	one	object[7]|abstract[8]	giv[7]|new[8]	_	_
2-19	127-136	ionizable	object[7]|abstract[8]	giv[7]|new[8]	_	_
2-20	137-138	N	object[7]|abstract[8]	giv[7]|new[8]	_	_
2-21	139-140	,	_	_	_	_
2-22	141-146	there	_	_	_	_
2-23	147-150	are	_	_	_	_
2-24	151-161	exceptions	abstract[9]	new[9]	_	_
2-25	162-163	,	abstract[9]	new[9]	_	_
2-26	164-173	including	abstract[9]	new[9]	_	_
2-27	174-184	lophotoxin	abstract[9]|person	new[9]|new	_	_
2-28	185-186	,	abstract[9]	new[9]	_	_
2-29	187-190	the	abstract[9]|animal[11]	new[9]|new[11]	_	_
2-30	191-205	neonicotinoids	abstract[9]|animal[11]	new[9]|new[11]	_	_
2-31	206-209	and	abstract[9]	new[9]	_	_
2-32	210-214	some	abstract[9]|abstract[13]	new[9]|giv[13]	coref	14-9[118_13]
2-33	215-223	recently	abstract[9]|abstract[13]	new[9]|giv[13]	_	_
2-34	224-235	synthesized	abstract[9]|abstract[13]	new[9]|giv[13]	_	_
2-35	236-246	pyrimidine	abstract[9]|abstract|abstract[13]	new[9]|new|giv[13]	_	_
2-36	247-255	agonists	abstract[9]|abstract[13]	new[9]|giv[13]	_	_
2-37	256-257	.	_	_	_	_

#Text=To optimize a molecule to serve as a drug or selective molecular probe of some receptor
3-1	258-260	To	_	_	_	_
3-2	261-269	optimize	_	_	_	_
3-3	270-271	a	object[14]	new[14]	_	_
3-4	272-280	molecule	object[14]	new[14]	_	_
3-5	281-283	to	_	_	_	_
3-6	284-289	serve	_	_	_	_
3-7	290-292	as	_	_	_	_
3-8	293-294	a	substance[15]	new[15]	_	_
3-9	295-299	drug	substance[15]	new[15]	_	_
3-10	300-302	or	_	_	_	_
3-11	303-312	selective	animal[16]	new[16]	ana	4-1[0_16]
3-12	313-322	molecular	animal[16]	new[16]	_	_
3-13	323-328	probe	animal[16]	new[16]	_	_
3-14	329-331	of	animal[16]	new[16]	_	_
3-15	332-336	some	animal[16]|substance[17]	new[16]|new[17]	coref	5-46[0_17]
3-16	337-345	receptor	animal[16]|substance[17]	new[16]|new[17]	_	_

#Text=it is important to identify the form in which it interacts optimally with its target .
4-1	346-348	it	animal	giv	ana	4-10
4-2	349-351	is	_	_	_	_
4-3	352-361	important	_	_	_	_
4-4	362-364	to	_	_	_	_
4-5	365-373	identify	_	_	_	_
4-6	374-377	the	abstract[19]	new[19]	coref	5-10[28_19]
4-7	378-382	form	abstract[19]	new[19]	_	_
4-8	383-385	in	abstract[19]	new[19]	_	_
4-9	386-391	which	abstract[19]	new[19]	_	_
4-10	392-394	it	abstract[19]|animal	new[19]|giv	ana	4-14
4-11	395-404	interacts	abstract[19]	new[19]	_	_
4-12	405-414	optimally	abstract[19]	new[19]	_	_
4-13	415-419	with	abstract[19]	new[19]	_	_
4-14	420-423	its	abstract[19]|animal|abstract[22]	new[19]|giv|new[22]	coref	5-44[37_22]
4-15	424-430	target	abstract[19]|abstract[22]	new[19]|new[22]	_	_
4-16	431-432	.	_	_	_	_

#Text=In the case of anabaseine , our identification of the cyclic iminium form as the most active ( and possibly the only ) form suggests that structural modifications that enhance the basicity of its tetrahydropyridyl nitrogen will enhance potency and possibly selectivity for the intended receptor target .
5-1	433-435	In	_	_	_	_
5-2	436-439	the	abstract[23]	new[23]	_	_
5-3	440-444	case	abstract[23]	new[23]	_	_
5-4	445-447	of	abstract[23]	new[23]	_	_
5-5	448-458	anabaseine	abstract[23]|substance	new[23]|new	ana	5-34
5-6	459-460	,	_	_	_	_
5-7	461-464	our	person|abstract[26]	acc|new[26]	ana	12-60
5-8	465-479	identification	abstract[26]	new[26]	_	_
5-9	480-482	of	abstract[26]	new[26]	_	_
5-10	483-486	the	abstract[26]|abstract[28]	new[26]|giv[28]	coref	5-15[29_28]
5-11	487-493	cyclic	abstract[26]|abstract[28]	new[26]|giv[28]	_	_
5-12	494-501	iminium	abstract[26]|substance|abstract[28]	new[26]|new|giv[28]	coref	8-15
5-13	502-506	form	abstract[26]|abstract[28]	new[26]|giv[28]	_	_
5-14	507-509	as	abstract[26]	new[26]	_	_
5-15	510-513	the	abstract[26]|abstract[29]	new[26]|giv[29]	coref	8-13[60_29]
5-16	514-518	most	abstract[26]|abstract[29]	new[26]|giv[29]	_	_
5-17	519-525	active	abstract[26]|abstract[29]	new[26]|giv[29]	_	_
5-18	526-527	(	abstract[26]|abstract[29]	new[26]|giv[29]	_	_
5-19	528-531	and	abstract[26]|abstract[29]	new[26]|giv[29]	_	_
5-20	532-540	possibly	abstract[26]|abstract[29]	new[26]|giv[29]	_	_
5-21	541-544	the	abstract[26]|abstract[29]	new[26]|giv[29]	_	_
5-22	545-549	only	abstract[26]|abstract[29]	new[26]|giv[29]	_	_
5-23	550-551	)	abstract[26]|abstract[29]	new[26]|giv[29]	_	_
5-24	552-556	form	abstract[26]|abstract[29]	new[26]|giv[29]	_	_
5-25	557-565	suggests	_	_	_	_
5-26	566-570	that	_	_	_	_
5-27	571-581	structural	abstract[30]	new[30]	_	_
5-28	582-595	modifications	abstract[30]	new[30]	_	_
5-29	596-600	that	abstract[30]	new[30]	_	_
5-30	601-608	enhance	abstract[30]	new[30]	_	_
5-31	609-612	the	abstract[30]|abstract[31]	new[30]|new[31]	_	_
5-32	613-621	basicity	abstract[30]|abstract[31]	new[30]|new[31]	_	_
5-33	622-624	of	abstract[30]|abstract[31]	new[30]|new[31]	_	_
5-34	625-628	its	abstract[30]|abstract[31]|substance|substance[33]	new[30]|new[31]|giv|new[33]	coref	8-18
5-35	629-646	tetrahydropyridyl	abstract[30]|abstract[31]|substance[33]	new[30]|new[31]|new[33]	_	_
5-36	647-655	nitrogen	abstract[30]|abstract[31]|substance[33]	new[30]|new[31]|new[33]	_	_
5-37	656-660	will	_	_	_	_
5-38	661-668	enhance	_	_	_	_
5-39	669-676	potency	abstract	new	coref	23-14[163_0]
5-40	677-680	and	_	_	_	_
5-41	681-689	possibly	abstract[35]	new[35]	_	_
5-42	690-701	selectivity	abstract[35]	new[35]	_	_
5-43	702-705	for	abstract[35]	new[35]	_	_
5-44	706-709	the	abstract[35]|abstract[37]	new[35]|giv[37]	_	_
5-45	710-718	intended	abstract[35]|abstract[37]	new[35]|giv[37]	_	_
5-46	719-727	receptor	abstract[35]|substance|abstract[37]	new[35]|giv|giv[37]	_	_
5-47	728-734	target	abstract[35]|abstract[37]	new[35]|giv[37]	_	_
5-48	735-736	.	_	_	_	_

#Text=In fact , a major improvement in stability occurs with addition at the 3-position of the tetrahydropyridyl ring of an electron-conjugated system containing an aromatic ring , as in 3-(4-dimethylaminobenzylidene)-anabaseine or 3-(2,4-dimethoxybenzylidene)-anabaseine , also called GTS-21 .
6-1	737-739	In	_	_	_	_
6-2	740-744	fact	_	_	_	_
6-3	745-746	,	_	_	_	_
6-4	747-748	a	abstract[38]	new[38]	_	_
6-5	749-754	major	abstract[38]	new[38]	_	_
6-6	755-766	improvement	abstract[38]	new[38]	_	_
6-7	767-769	in	abstract[38]	new[38]	_	_
6-8	770-779	stability	abstract[38]|abstract	new[38]|new	_	_
6-9	780-786	occurs	_	_	_	_
6-10	787-791	with	_	_	_	_
6-11	792-800	addition	event[40]	new[40]	_	_
6-12	801-803	at	event[40]	new[40]	_	_
6-13	804-807	the	event[40]|abstract[41]	new[40]|new[41]	_	_
6-14	808-818	3-position	event[40]|abstract[41]	new[40]|new[41]	_	_
6-15	819-821	of	event[40]|abstract[41]	new[40]|new[41]	_	_
6-16	822-825	the	event[40]|abstract[41]|object[42]	new[40]|new[41]|new[42]	coref	6-24[44_42]
6-17	826-843	tetrahydropyridyl	event[40]|abstract[41]|object[42]	new[40]|new[41]|new[42]	_	_
6-18	844-848	ring	event[40]|abstract[41]|object[42]	new[40]|new[41]|new[42]	_	_
6-19	849-851	of	event[40]|abstract[41]|object[42]	new[40]|new[41]|new[42]	_	_
6-20	852-854	an	event[40]|abstract[41]|object[42]|abstract[43]	new[40]|new[41]|new[42]|new[43]	_	_
6-21	855-874	electron-conjugated	event[40]|abstract[41]|object[42]|abstract[43]	new[40]|new[41]|new[42]|new[43]	_	_
6-22	875-881	system	event[40]|abstract[41]|object[42]|abstract[43]	new[40]|new[41]|new[42]|new[43]	_	_
6-23	882-892	containing	event[40]|abstract[41]|object[42]|abstract[43]	new[40]|new[41]|new[42]|new[43]	_	_
6-24	893-895	an	event[40]|abstract[41]|object[42]|abstract[43]|object[44]	new[40]|new[41]|new[42]|new[43]|giv[44]	coref	7-7[0_44]
6-25	896-904	aromatic	event[40]|abstract[41]|object[42]|abstract[43]|object[44]	new[40]|new[41]|new[42]|new[43]|giv[44]	_	_
6-26	905-909	ring	event[40]|abstract[41]|object[42]|abstract[43]|object[44]	new[40]|new[41]|new[42]|new[43]|giv[44]	_	_
6-27	910-911	,	_	_	_	_
6-28	912-914	as	_	_	_	_
6-29	915-917	in	_	_	_	_
6-30	918-959	3-(4-dimethylaminobenzylidene)-anabaseine	event	new	_	_
6-31	960-962	or	_	_	_	_
6-32	963-1002	3-(2,4-dimethoxybenzylidene)-anabaseine	event[46]	new[46]	_	_
6-33	1003-1004	,	event[46]	new[46]	_	_
6-34	1005-1009	also	event[46]	new[46]	_	_
6-35	1010-1016	called	event[46]	new[46]	_	_
6-36	1017-1023	GTS-21	event[46]|abstract	new[46]|new	_	_
6-37	1024-1025	.	_	_	_	_

#Text=These anabaseine derivatives do not undergo ring opening ( hydrolysis of the imine bond ) under physiological conditions , due to their extended π electron conjugation .
7-1	1026-1031	These	substance[48]	new[48]	ana	7-22[0_48]
7-2	1032-1042	anabaseine	substance[48]	new[48]	_	_
7-3	1043-1054	derivatives	substance[48]	new[48]	_	_
7-4	1055-1057	do	_	_	_	_
7-5	1058-1061	not	_	_	_	_
7-6	1062-1069	undergo	_	_	_	_
7-7	1070-1074	ring	object|abstract[50]	giv|new[50]	appos|coref	7-10[51_50]|24-15[171_0]
7-8	1075-1082	opening	abstract[50]	new[50]	_	_
7-9	1083-1084	(	_	_	_	_
7-10	1085-1095	hydrolysis	abstract[51]	giv[51]	_	_
7-11	1096-1098	of	abstract[51]	giv[51]	_	_
7-12	1099-1102	the	abstract[51]|abstract[53]	giv[51]|new[53]	coref	24-20[173_53]
7-13	1103-1108	imine	abstract[51]|substance|abstract[53]	giv[51]|new|new[53]	_	_
7-14	1109-1113	bond	abstract[51]|abstract[53]	giv[51]|new[53]	_	_
7-15	1114-1115	)	_	_	_	_
7-16	1116-1121	under	_	_	_	_
7-17	1122-1135	physiological	abstract[54]	new[54]	_	_
7-18	1136-1146	conditions	abstract[54]	new[54]	_	_
7-19	1147-1148	,	_	_	_	_
7-20	1149-1152	due	_	_	_	_
7-21	1153-1155	to	_	_	_	_
7-22	1156-1161	their	substance|abstract[57]	giv|new[57]	ana	8-3[0_57]
7-23	1162-1170	extended	abstract[57]	new[57]	_	_
7-24	1171-1172	π	abstract[57]	new[57]	_	_
7-25	1173-1181	electron	substance|abstract[57]	new|new[57]	_	_
7-26	1182-1193	conjugation	abstract[57]	new[57]	_	_
7-27	1194-1195	.	_	_	_	_

#Text=Previously , it was assumed ( but not experimentally tested ) that the cyclic iminium form of anabaseine is the one which binds avidly to the ACh binding site in nAChRs .
8-1	1196-1206	Previously	_	_	_	_
8-2	1207-1208	,	_	_	_	_
8-3	1209-1211	it	abstract	giv	_	_
8-4	1212-1215	was	_	_	_	_
8-5	1216-1223	assumed	_	_	_	_
8-6	1224-1225	(	_	_	_	_
8-7	1226-1229	but	_	_	_	_
8-8	1230-1233	not	_	_	_	_
8-9	1234-1248	experimentally	_	_	_	_
8-10	1249-1255	tested	_	_	_	_
8-11	1256-1257	)	_	_	_	_
8-12	1258-1262	that	_	_	_	_
8-13	1263-1266	the	abstract[60]	giv[60]	coref	8-20[62_60]
8-14	1267-1273	cyclic	abstract[60]	giv[60]	_	_
8-15	1274-1281	iminium	substance|abstract[60]	giv|giv[60]	coref	10-18[78_0]
8-16	1282-1286	form	abstract[60]	giv[60]	_	_
8-17	1287-1289	of	abstract[60]	giv[60]	_	_
8-18	1290-1300	anabaseine	abstract[60]|substance	giv[60]|giv	coref	10-5[76_0]
8-19	1301-1303	is	_	_	_	_
8-20	1304-1307	the	abstract[62]	giv[62]	coref	9-1[67_62]
8-21	1308-1311	one	abstract[62]	giv[62]	_	_
8-22	1312-1317	which	abstract[62]	giv[62]	_	_
8-23	1318-1323	binds	abstract[62]	giv[62]	_	_
8-24	1324-1330	avidly	abstract[62]	giv[62]	_	_
8-25	1331-1333	to	abstract[62]	giv[62]	_	_
8-26	1334-1337	the	abstract[62]|place[65]	giv[62]|new[65]	coref	24-32[178_65]
8-27	1338-1341	ACh	abstract[62]|abstract|place[65]	giv[62]|giv|new[65]	_	_
8-28	1342-1349	binding	abstract[62]|object|place[65]	giv[62]|new|new[65]	coref	10-35
8-29	1350-1354	site	abstract[62]|place[65]	giv[62]|new[65]	_	_
8-30	1355-1357	in	abstract[62]|place[65]	giv[62]|new[65]	_	_
8-31	1358-1364	nAChRs	abstract[62]|place[65]|substance	giv[62]|new[65]|new	coref	12-50
8-32	1365-1366	.	_	_	_	_

#Text=This form was modeled to fit into a muscle type homology model .
9-1	1367-1371	This	abstract[67]	giv[67]	_	_
9-2	1372-1376	form	abstract[67]	giv[67]	_	_
9-3	1377-1380	was	_	_	_	_
9-4	1381-1388	modeled	_	_	_	_
9-5	1389-1391	to	_	_	_	_
9-6	1392-1395	fit	_	_	_	_
9-7	1396-1400	into	_	_	_	_
9-8	1401-1402	a	abstract[71]	new[71]	_	_
9-9	1403-1409	muscle	object|object[69]|abstract[71]	new|new[69]|new[71]	_	_
9-10	1410-1414	type	object[69]|abstract[71]	new[69]|new[71]	_	_
9-11	1415-1423	homology	abstract|abstract[71]	new|new[71]	_	_
9-12	1424-1429	model	abstract[71]	new[71]	_	_
9-13	1430-1431	.	_	_	_	_

#Text=The crystal structure of the molluscan acetylcholine binding protein binding anabaseine actually was derived from crystals containing both the cyclic iminium and the open-chain monocationic form of anabaseine occupying some of the five identical binding sites .
10-1	1432-1435	The	abstract[73]	new[73]	coref	12-33[99_73]
10-2	1436-1443	crystal	place|abstract[73]	new|new[73]	coref	12-34
10-3	1444-1453	structure	abstract[73]	new[73]	_	_
10-4	1454-1456	of	abstract[73]	new[73]	_	_
10-5	1457-1460	the	abstract[73]|substance[76]	new[73]|giv[76]	coref	10-28[0_76]
10-6	1461-1470	molluscan	abstract[73]|substance[75]|substance[76]	new[73]|new[75]|giv[76]	_	_
10-7	1471-1484	acetylcholine	abstract[73]|substance|substance[75]|substance[76]	new[73]|new|new[75]|giv[76]	_	_
10-8	1485-1492	binding	abstract[73]|substance[75]|substance[76]	new[73]|new[75]|giv[76]	_	_
10-9	1493-1500	protein	abstract[73]|substance[75]|substance[76]	new[73]|new[75]|giv[76]	_	_
10-10	1501-1508	binding	abstract[73]|substance[76]	new[73]|giv[76]	_	_
10-11	1509-1519	anabaseine	abstract[73]|substance[76]	new[73]|giv[76]	_	_
10-12	1520-1528	actually	_	_	_	_
10-13	1529-1532	was	_	_	_	_
10-14	1533-1540	derived	_	_	_	_
10-15	1541-1545	from	_	_	_	_
10-16	1546-1554	crystals	object[77]	new[77]	coref	12-5[92_77]
10-17	1555-1565	containing	object[77]	new[77]	_	_
10-18	1566-1570	both	object[77]|substance[78]|substance[79]	new[77]|giv[78]|new[79]	ana|coref	10-30[82_79]|11-2[85_78]
10-19	1571-1574	the	object[77]|substance[78]|substance[79]	new[77]|giv[78]|new[79]	_	_
10-20	1575-1581	cyclic	object[77]|substance[78]|substance[79]	new[77]|giv[78]|new[79]	_	_
10-21	1582-1589	iminium	object[77]|substance[78]|substance[79]	new[77]|giv[78]|new[79]	_	_
10-22	1590-1593	and	object[77]|substance[79]	new[77]|new[79]	_	_
10-23	1594-1597	the	object[77]|substance[79]|abstract[80]	new[77]|new[79]|new[80]	coref	11-7[86_80]
10-24	1598-1608	open-chain	object[77]|substance[79]|abstract[80]	new[77]|new[79]|new[80]	_	_
10-25	1609-1621	monocationic	object[77]|substance[79]|abstract[80]	new[77]|new[79]|new[80]	_	_
10-26	1622-1626	form	object[77]|substance[79]|abstract[80]	new[77]|new[79]|new[80]	_	_
10-27	1627-1629	of	object[77]|substance[79]|abstract[80]	new[77]|new[79]|new[80]	_	_
10-28	1630-1640	anabaseine	object[77]|substance[79]|abstract[80]|substance	new[77]|new[79]|new[80]|giv	coref	12-10
10-29	1641-1650	occupying	_	_	_	_
10-30	1651-1655	some	substance[82]	giv[82]	_	_
10-31	1656-1658	of	substance[82]	giv[82]	_	_
10-32	1659-1662	the	substance[82]|place[84]	giv[82]|giv[84]	coref	12-16[95_84]
10-33	1663-1667	five	substance[82]|place[84]	giv[82]|giv[84]	_	_
10-34	1668-1677	identical	substance[82]|place[84]	giv[82]|giv[84]	_	_
10-35	1678-1685	binding	substance[82]|object|place[84]	giv[82]|giv|giv[84]	coref	24-35
10-36	1686-1691	sites	substance[82]|place[84]	giv[82]|giv[84]	_	_
10-37	1692-1693	.	_	_	_	_

#Text=Unlike the cyclic iminium , the ammonium-ketone form ammonium group did not insert into the “ aromatic box . ”
11-1	1694-1700	Unlike	_	_	_	_
11-2	1701-1704	the	substance[85]	giv[85]	coref	23-21[0_85]
11-3	1705-1711	cyclic	substance[85]	giv[85]	_	_
11-4	1712-1719	iminium	substance[85]	giv[85]	_	_
11-5	1720-1721	,	_	_	_	_
11-6	1722-1725	the	person[88]	new[88]	_	_
11-7	1726-1741	ammonium-ketone	abstract[86]|person[88]	giv[86]|new[88]	coref	12-29[97_86]
11-8	1742-1746	form	abstract[86]|person[88]	giv[86]|new[88]	_	_
11-9	1747-1755	ammonium	object|person[88]	new|new[88]	_	_
11-10	1756-1761	group	person[88]	new[88]	_	_
11-11	1762-1765	did	_	_	_	_
11-12	1766-1769	not	_	_	_	_
11-13	1770-1776	insert	_	_	_	_
11-14	1777-1781	into	_	_	_	_
11-15	1782-1785	the	object[89]	new[89]	coref	24-28[175_89]
11-16	1786-1787	“	object[89]	new[89]	_	_
11-17	1788-1796	aromatic	object[89]	new[89]	_	_
11-18	1797-1800	box	object[89]	new[89]	_	_
11-19	1801-1802	.	_	_	_	_
11-20	1803-1804	”	_	_	_	_

#Text=In the preparation of the AChBP-anabaseine crystals very high anabaseine concentrations were used so that most of the five sites would be occupied ; therefore the presence of the ammonium-ketone form in the crystal structure does not necessarily indicate that this form of anabaseine would bind to AChBPs and nAChRs at the low concentrations of anabaseine that occur in our in vitro functional and binding studies .
12-1	1805-1807	In	_	_	_	_
12-2	1808-1811	the	abstract[90]	new[90]	_	_
12-3	1812-1823	preparation	abstract[90]	new[90]	_	_
12-4	1824-1826	of	abstract[90]	new[90]	_	_
12-5	1827-1830	the	abstract[90]|object[92]	new[90]|giv[92]	_	_
12-6	1831-1847	AChBP-anabaseine	abstract[90]|abstract|object[92]	new[90]|new|giv[92]	_	_
12-7	1848-1856	crystals	abstract[90]|object[92]	new[90]|giv[92]	_	_
12-8	1857-1861	very	abstract[94]	new[94]	coref	30-20[221_94]
12-9	1862-1866	high	abstract[94]	new[94]	_	_
12-10	1867-1877	anabaseine	substance|abstract[94]	giv|new[94]	coref	12-44
12-11	1878-1892	concentrations	abstract[94]	new[94]	_	_
12-12	1893-1897	were	_	_	_	_
12-13	1898-1902	used	_	_	_	_
12-14	1903-1905	so	_	_	_	_
12-15	1906-1910	that	_	_	_	_
12-16	1911-1915	most	place[95]	giv[95]	_	_
12-17	1916-1918	of	place[95]	giv[95]	_	_
12-18	1919-1922	the	place[95]	giv[95]	_	_
12-19	1923-1927	five	place[95]	giv[95]	_	_
12-20	1928-1933	sites	place[95]	giv[95]	_	_
12-21	1934-1939	would	_	_	_	_
12-22	1940-1942	be	_	_	_	_
12-23	1943-1951	occupied	_	_	_	_
12-24	1952-1953	;	_	_	_	_
12-25	1954-1963	therefore	_	_	_	_
12-26	1964-1967	the	abstract[96]	new[96]	_	_
12-27	1968-1976	presence	abstract[96]	new[96]	_	_
12-28	1977-1979	of	abstract[96]	new[96]	_	_
12-29	1980-1983	the	abstract[96]|abstract[97]	new[96]|giv[97]	coref	18-11[144_97]
12-30	1984-1999	ammonium-ketone	abstract[96]|abstract[97]	new[96]|giv[97]	_	_
12-31	2000-2004	form	abstract[96]|abstract[97]	new[96]|giv[97]	_	_
12-32	2005-2007	in	abstract[96]|abstract[97]	new[96]|giv[97]	_	_
12-33	2008-2011	the	abstract[96]|abstract[97]|abstract[99]	new[96]|giv[97]|giv[99]	_	_
12-34	2012-2019	crystal	abstract[96]|abstract[97]|place|abstract[99]	new[96]|giv[97]|giv|giv[99]	_	_
12-35	2020-2029	structure	abstract[96]|abstract[97]|abstract[99]	new[96]|giv[97]|giv[99]	_	_
12-36	2030-2034	does	_	_	_	_
12-37	2035-2038	not	_	_	_	_
12-38	2039-2050	necessarily	_	_	_	_
12-39	2051-2059	indicate	_	_	_	_
12-40	2060-2064	that	_	_	_	_
12-41	2065-2069	this	substance[100]	new[100]	_	_
12-42	2070-2074	form	substance[100]	new[100]	_	_
12-43	2075-2077	of	substance[100]	new[100]	_	_
12-44	2078-2088	anabaseine	substance[100]|substance	new[100]|giv	coref	12-56[105_0]
12-45	2089-2094	would	_	_	_	_
12-46	2095-2099	bind	_	_	_	_
12-47	2100-2102	to	_	_	_	_
12-48	2103-2109	AChBPs	abstract	new	_	_
12-49	2110-2113	and	_	_	_	_
12-50	2114-2120	nAChRs	substance	giv	coref	13-10[111_0]
12-51	2121-2123	at	_	_	_	_
12-52	2124-2127	the	animal[104]	new[104]	_	_
12-53	2128-2131	low	animal[104]	new[104]	_	_
12-54	2132-2146	concentrations	animal[104]	new[104]	_	_
12-55	2147-2149	of	animal[104]	new[104]	_	_
12-56	2150-2160	anabaseine	animal[104]|substance[105]	new[104]|giv[105]	coref	17-37[0_105]
12-57	2161-2165	that	animal[104]|substance[105]	new[104]|giv[105]	_	_
12-58	2166-2171	occur	animal[104]|substance[105]	new[104]|giv[105]	_	_
12-59	2172-2174	in	animal[104]|substance[105]	new[104]|giv[105]	_	_
12-60	2175-2178	our	animal[104]|substance[105]|person|abstract[107]	new[104]|giv[105]|giv|new[107]	ana|coref	16-1|26-20[192_107]
12-61	2179-2181	in	animal[104]|substance[105]|abstract[107]	new[104]|giv[105]|new[107]	_	_
12-62	2182-2187	vitro	animal[104]|substance[105]|abstract[107]	new[104]|giv[105]|new[107]	_	_
12-63	2188-2198	functional	animal[104]|substance[105]|abstract[107]	new[104]|giv[105]|new[107]	_	_
12-64	2199-2202	and	animal[104]|substance[105]|abstract[107]	new[104]|giv[105]|new[107]	_	_
12-65	2203-2210	binding	animal[104]|substance[105]|abstract[107]	new[104]|giv[105]|new[107]	_	_
12-66	2211-2218	studies	animal[104]|substance[105]|abstract[107]	new[104]|giv[105]|new[107]	_	_
12-67	2219-2220	.	_	_	_	_

#Text=The ability of a variety of 2-(aryl)-1,4,5,6-tetrahydropyrmidines to block neuromuscular nAChRs and produce teratogenic effects in chick embryos was reported long ago .
13-1	2221-2224	The	abstract[108]	new[108]	ana	14-1[115_108]
13-2	2225-2232	ability	abstract[108]	new[108]	_	_
13-3	2233-2235	of	abstract[108]	new[108]	_	_
13-4	2236-2237	a	abstract[108]|abstract[109]	new[108]|new[109]	_	_
13-5	2238-2245	variety	abstract[108]|abstract[109]	new[108]|new[109]	_	_
13-6	2246-2248	of	abstract[108]|abstract[109]	new[108]|new[109]	_	_
13-7	2249-2286	2-(aryl)-1,4,5,6-tetrahydropyrmidines	abstract[108]|abstract[109]|abstract	new[108]|new[109]|new	_	_
13-8	2287-2289	to	abstract[108]	new[108]	_	_
13-9	2290-2295	block	abstract[108]	new[108]	_	_
13-10	2296-2309	neuromuscular	abstract[108]|substance[111]	new[108]|giv[111]	coref	16-12[130_111]
13-11	2310-2316	nAChRs	abstract[108]|substance[111]	new[108]|giv[111]	_	_
13-12	2317-2320	and	abstract[108]	new[108]	_	_
13-13	2321-2328	produce	abstract[108]	new[108]	_	_
13-14	2329-2340	teratogenic	abstract[108]|abstract[112]	new[108]|new[112]	_	_
13-15	2341-2348	effects	abstract[108]|abstract[112]	new[108]|new[112]	_	_
13-16	2349-2351	in	abstract[108]|abstract[112]	new[108]|new[112]	_	_
13-17	2352-2357	chick	abstract[108]|abstract[112]|animal|animal[114]	new[108]|new[112]|new|new[114]	_	_
13-18	2358-2365	embryos	abstract[108]|abstract[112]|animal[114]	new[108]|new[112]|new[114]	_	_
13-19	2366-2369	was	_	_	_	_
13-20	2370-2378	reported	_	_	_	_
13-21	2379-2383	long	_	_	_	_
13-22	2384-2387	ago	_	_	_	_
13-23	2388-2389	.	_	_	_	_

#Text=Some of these compounds were reported to be nAChR agonists .
14-1	2390-2394	Some	abstract[115]	giv[115]	_	_
14-2	2395-2397	of	abstract[115]	giv[115]	_	_
14-3	2398-2403	these	abstract[115]|substance[116]	giv[115]|new[116]	coref	17-1[131_116]
14-4	2404-2413	compounds	abstract[115]|substance[116]	giv[115]|new[116]	_	_
14-5	2414-2418	were	_	_	_	_
14-6	2419-2427	reported	_	_	_	_
14-7	2428-2430	to	_	_	_	_
14-8	2431-2433	be	_	_	_	_
14-9	2434-2439	nAChR	abstract|abstract[118]	giv|giv[118]	coref	24-33
14-10	2440-2448	agonists	abstract[118]	giv[118]	_	_
14-11	2449-2450	.	_	_	_	_

#Text=The only study of PTHP on neurons was that of Upshall et al. on leech Retzius cells .
15-1	2451-2454	The	abstract[119]	new[119]	coref	17-6[133_119]
15-2	2455-2459	only	abstract[119]	new[119]	_	_
15-3	2460-2465	study	abstract[119]	new[119]	_	_
15-4	2466-2468	of	abstract[119]	new[119]	_	_
15-5	2469-2473	PTHP	abstract[119]|abstract	new[119]|new	coref	16-6
15-6	2474-2476	on	abstract[119]	new[119]	_	_
15-7	2477-2484	neurons	abstract[119]|animal	new[119]|new	_	_
15-8	2485-2488	was	_	_	_	_
15-9	2489-2493	that	_	_	_	_
15-10	2494-2496	of	_	_	_	_
15-11	2497-2504	Upshall	person	new	ana	29-1
15-12	2505-2507	et	_	_	_	_
15-13	2508-2511	al.	_	_	_	_
15-14	2512-2514	on	_	_	_	_
15-15	2515-2520	leech	animal|animal[125]	new|new[125]	_	_
15-16	2521-2528	Retzius	person|animal[125]	new|new[125]	_	_
15-17	2529-2534	cells	animal[125]	new[125]	_	_
15-18	2535-2536	.	_	_	_	_

#Text=Our results also indicate that PTHP is a potent agonist at neuronal as well as neuromuscular nAChRs .
16-1	2537-2540	Our	person|abstract[127]	giv|new[127]	_	_
16-2	2541-2548	results	abstract[127]	new[127]	_	_
16-3	2549-2553	also	_	_	_	_
16-4	2554-2562	indicate	_	_	_	_
16-5	2563-2567	that	_	_	_	_
16-6	2568-2572	PTHP	abstract	giv	coref	16-8[129_0]
16-7	2573-2575	is	_	_	_	_
16-8	2576-2577	a	abstract[129]	giv[129]	coref	17-14[0_129]
16-9	2578-2584	potent	abstract[129]	giv[129]	_	_
16-10	2585-2592	agonist	abstract[129]	giv[129]	_	_
16-11	2593-2595	at	abstract[129]	giv[129]	_	_
16-12	2596-2604	neuronal	abstract[129]|substance[130]	giv[129]|giv[130]	coref	26-1[189_130]
16-13	2605-2607	as	abstract[129]|substance[130]	giv[129]|giv[130]	_	_
16-14	2608-2612	well	abstract[129]|substance[130]	giv[129]|giv[130]	_	_
16-15	2613-2615	as	abstract[129]|substance[130]	giv[129]|giv[130]	_	_
16-16	2616-2629	neuromuscular	abstract[129]|substance[130]	giv[129]|giv[130]	_	_
16-17	2630-2636	nAChRs	abstract[129]|substance[130]	giv[129]|giv[130]	_	_
16-18	2637-2638	.	_	_	_	_

#Text=The 2-aryl compounds reported in the Brimblecombe et al. study did not include PTHP or other compounds having a 2-(3-pyridyl)- substituent , which is known to be essential for the agonist activity of nicotine and of anabaseine .
17-1	2639-2642	The	substance[131]	giv[131]	coref	17-16[136_131]
17-2	2643-2649	2-aryl	substance[131]	giv[131]	_	_
17-3	2650-2659	compounds	substance[131]	giv[131]	_	_
17-4	2660-2668	reported	substance[131]	giv[131]	_	_
17-5	2669-2671	in	substance[131]	giv[131]	_	_
17-6	2672-2675	the	substance[131]|abstract[133]	giv[131]|giv[133]	_	_
17-7	2676-2688	Brimblecombe	substance[131]|person|abstract[133]	giv[131]|new|giv[133]	_	_
17-8	2689-2691	et	substance[131]|abstract[133]	giv[131]|giv[133]	_	_
17-9	2692-2695	al.	substance[131]|abstract[133]	giv[131]|giv[133]	_	_
17-10	2696-2701	study	substance[131]|abstract[133]	giv[131]|giv[133]	_	_
17-11	2702-2705	did	_	_	_	_
17-12	2706-2709	not	_	_	_	_
17-13	2710-2717	include	_	_	_	_
17-14	2718-2722	PTHP	abstract|substance[135]	giv|new[135]	coref|coref	18-2|19-4[156_135]
17-15	2723-2725	or	substance[135]	new[135]	_	_
17-16	2726-2731	other	substance[135]|substance[136]	new[135]|giv[136]	_	_
17-17	2732-2741	compounds	substance[135]|substance[136]	new[135]|giv[136]	_	_
17-18	2742-2748	having	substance[135]|substance[136]	new[135]|giv[136]	_	_
17-19	2749-2750	a	substance[135]|substance[136]|abstract[137]	new[135]|giv[136]|new[137]	_	_
17-20	2751-2765	2-(3-pyridyl)-	substance[135]|substance[136]|abstract[137]	new[135]|giv[136]|new[137]	_	_
17-21	2766-2777	substituent	substance[135]|substance[136]|abstract[137]	new[135]|giv[136]|new[137]	_	_
17-22	2778-2779	,	substance[135]|substance[136]|abstract[137]	new[135]|giv[136]|new[137]	_	_
17-23	2780-2785	which	substance[135]|substance[136]|abstract[137]	new[135]|giv[136]|new[137]	_	_
17-24	2786-2788	is	substance[135]|substance[136]|abstract[137]	new[135]|giv[136]|new[137]	_	_
17-25	2789-2794	known	substance[135]|substance[136]|abstract[137]	new[135]|giv[136]|new[137]	_	_
17-26	2795-2797	to	substance[135]|substance[136]|abstract[137]	new[135]|giv[136]|new[137]	_	_
17-27	2798-2800	be	substance[135]|substance[136]|abstract[137]	new[135]|giv[136]|new[137]	_	_
17-28	2801-2810	essential	substance[135]|substance[136]|abstract[137]	new[135]|giv[136]|new[137]	_	_
17-29	2811-2814	for	_	_	_	_
17-30	2815-2818	the	abstract[138]	new[138]	coref	27-5[197_138]
17-31	2819-2826	agonist	abstract[138]	new[138]	_	_
17-32	2827-2835	activity	abstract[138]	new[138]	_	_
17-33	2836-2838	of	abstract[138]	new[138]	_	_
17-34	2839-2847	nicotine	abstract[138]|substance	new[138]|new	_	_
17-35	2848-2851	and	_	_	_	_
17-36	2852-2854	of	_	_	_	_
17-37	2855-2865	anabaseine	substance	giv	coref	18-7
17-38	2866-2867	.	_	_	_	_

#Text=For PTHP to be equipotent with anabaseine , based on the I+ form being the only active form , its EC50 would need to be ~1/3 of the EC50 of anabaseine , since the anabaseine ( I+ ) is ~1/3 of its total concentration .
18-1	2868-2871	For	_	_	_	_
18-2	2872-2876	PTHP	abstract	giv	coref	19-4
18-3	2877-2879	to	_	_	_	_
18-4	2880-2882	be	_	_	_	_
18-5	2883-2893	equipotent	_	_	_	_
18-6	2894-2898	with	_	_	_	_
18-7	2899-2909	anabaseine	substance	giv	ana	18-20
18-8	2910-2911	,	_	_	_	_
18-9	2912-2917	based	_	_	_	_
18-10	2918-2920	on	_	_	_	_
18-11	2921-2924	the	abstract[144]	giv[144]	coref	18-15[145_144]
18-12	2925-2927	I+	abstract|abstract[144]	new|giv[144]	appos	18-37
18-13	2928-2932	form	abstract[144]	giv[144]	_	_
18-14	2933-2938	being	_	_	_	_
18-15	2939-2942	the	abstract[145]	giv[145]	coref	23-18[166_145]
18-16	2943-2947	only	abstract[145]	giv[145]	_	_
18-17	2948-2954	active	abstract[145]	giv[145]	_	_
18-18	2955-2959	form	abstract[145]	giv[145]	_	_
18-19	2960-2961	,	_	_	_	_
18-20	2962-2965	its	substance|abstract[147]	giv|new[147]	coref|coref	18-28[148_147]|18-31
18-21	2966-2970	EC50	abstract[147]	new[147]	_	_
18-22	2971-2976	would	_	_	_	_
18-23	2977-2981	need	_	_	_	_
18-24	2982-2984	to	_	_	_	_
18-25	2985-2987	be	_	_	_	_
18-26	2988-2992	~1/3	_	_	_	_
18-27	2993-2995	of	_	_	_	_
18-28	2996-2999	the	abstract[148]	giv[148]	_	_
18-29	3000-3004	EC50	abstract[148]	giv[148]	_	_
18-30	3005-3007	of	abstract[148]	giv[148]	_	_
18-31	3008-3018	anabaseine	abstract[148]|substance	giv[148]|giv	coref	18-34[150_0]
18-32	3019-3020	,	_	_	_	_
18-33	3021-3026	since	_	_	_	_
18-34	3027-3030	the	substance[150]	giv[150]	ana	18-42[0_150]
18-35	3031-3041	anabaseine	substance[150]	giv[150]	_	_
18-36	3042-3043	(	_	_	_	_
18-37	3044-3046	I+	abstract	giv	_	_
18-38	3047-3048	)	_	_	_	_
18-39	3049-3051	is	_	_	_	_
18-40	3052-3056	~1/3	_	_	_	_
18-41	3057-3059	of	_	_	_	_
18-42	3060-3063	its	substance|abstract[153]	giv|new[153]	coref|coref	19-6|34-33[250_153]
18-43	3064-3069	total	abstract[153]	new[153]	_	_
18-44	3070-3083	concentration	abstract[153]	new[153]	_	_
18-45	3084-3085	.	_	_	_	_

#Text=The data for PTHP and anabaseine in
19-1	3086-3089	The	abstract[154]	new[154]	_	_
19-2	3090-3094	data	abstract[154]	new[154]	_	_
19-3	3095-3098	for	abstract[154]	new[154]	_	_
19-4	3099-3103	PTHP	abstract[154]|abstract|substance[156]	new[154]|giv|giv[156]	coref	23-8
19-5	3104-3107	and	abstract[154]|substance[156]	new[154]|giv[156]	_	_
19-6	3108-3118	anabaseine	abstract[154]|substance[156]|substance	new[154]|giv[156]|giv	coref	23-19
19-7	3119-3121	in	abstract[154]	new[154]	_	_

#Text=Figure 3
20-1	3122-3128	Figure	abstract[158]	new[158]	_	_
20-2	3129-3130	3	abstract[158]	new[158]	_	_

#Text=and
21-1	3131-3134	and	_	_	_	_

#Text=Figure 4
22-1	3135-3141	Figure	abstract[159]	new[159]	_	_
22-2	3142-3143	4	abstract[159]	new[159]	_	_

#Text=and in Table 1 , indicate that PTHP has approximately 30 % of the potency predicted for the anabaseine cyclic iminium form .
23-1	3144-3147	and	_	_	_	_
23-2	3148-3150	in	_	_	_	_
23-3	3151-3156	Table	abstract[160]	new[160]	_	_
23-4	3157-3158	1	abstract[160]	new[160]	_	_
23-5	3159-3160	,	_	_	_	_
23-6	3161-3169	indicate	_	_	_	_
23-7	3170-3174	that	_	_	_	_
23-8	3175-3179	PTHP	abstract	giv	_	_
23-9	3180-3183	has	_	_	_	_
23-10	3184-3197	approximately	abstract[162]	new[162]	_	_
23-11	3198-3200	30	abstract[162]	new[162]	_	_
23-12	3201-3202	%	abstract[162]	new[162]	_	_
23-13	3203-3205	of	abstract[162]	new[162]	_	_
23-14	3206-3209	the	abstract[162]|abstract[163]	new[162]|giv[163]	coref	24-5[168_163]
23-15	3210-3217	potency	abstract[162]|abstract[163]	new[162]|giv[163]	_	_
23-16	3218-3227	predicted	abstract[162]|abstract[163]	new[162]|giv[163]	_	_
23-17	3228-3231	for	abstract[162]|abstract[163]	new[162]|giv[163]	_	_
23-18	3232-3235	the	abstract[162]|abstract[163]|abstract[166]	new[162]|giv[163]|giv[166]	coref	28-11[204_166]
23-19	3236-3246	anabaseine	abstract[162]|abstract[163]|substance|abstract[166]	new[162]|giv[163]|giv|giv[166]	coref	29-32
23-20	3247-3253	cyclic	abstract[162]|abstract[163]|abstract[166]	new[162]|giv[163]|giv[166]	_	_
23-21	3254-3261	iminium	abstract[162]|abstract[163]|substance|abstract[166]	new[162]|giv[163]|giv|giv[166]	_	_
23-22	3262-3266	form	abstract[162]|abstract[163]|abstract[166]	new[162]|giv[163]|giv[166]	_	_
23-23	3267-3268	.	_	_	_	_

#Text=One possible explanation for this slightly inferior potency is that the additional N on the tetrahydropyrmidinyl ring must form an H bond with some other atom within the aromatic box of the nAChR orthosteric binding site and this may be energetically unfavorable .
24-1	3269-3272	One	abstract[167]	new[167]	_	_
24-2	3273-3281	possible	abstract[167]	new[167]	_	_
24-3	3282-3293	explanation	abstract[167]	new[167]	_	_
24-4	3294-3297	for	abstract[167]	new[167]	_	_
24-5	3298-3302	this	abstract[167]|abstract[168]	new[167]|giv[168]	coref	25-4[181_168]
24-6	3303-3311	slightly	abstract[167]|abstract[168]	new[167]|giv[168]	_	_
24-7	3312-3320	inferior	abstract[167]|abstract[168]	new[167]|giv[168]	_	_
24-8	3321-3328	potency	abstract[167]|abstract[168]	new[167]|giv[168]	_	_
24-9	3329-3331	is	_	_	_	_
24-10	3332-3336	that	_	_	_	_
24-11	3337-3340	the	abstract[169]	new[169]	_	_
24-12	3341-3351	additional	abstract[169]	new[169]	_	_
24-13	3352-3353	N	abstract[169]	new[169]	_	_
24-14	3354-3356	on	abstract[169]	new[169]	_	_
24-15	3357-3360	the	abstract[169]|object[171]	new[169]|giv[171]	_	_
24-16	3361-3381	tetrahydropyrmidinyl	abstract[169]|abstract|object[171]	new[169]|new|giv[171]	_	_
24-17	3382-3386	ring	abstract[169]|object[171]	new[169]|giv[171]	_	_
24-18	3387-3391	must	_	_	_	_
24-19	3392-3396	form	_	_	_	_
24-20	3397-3399	an	abstract[173]	giv[173]	ana	24-38[0_173]
24-21	3400-3401	H	person|abstract[173]	new|giv[173]	_	_
24-22	3402-3406	bond	abstract[173]	giv[173]	_	_
24-23	3407-3411	with	_	_	_	_
24-24	3412-3416	some	substance[174]	new[174]	_	_
24-25	3417-3422	other	substance[174]	new[174]	_	_
24-26	3423-3427	atom	substance[174]	new[174]	_	_
24-27	3428-3434	within	substance[174]	new[174]	_	_
24-28	3435-3438	the	substance[174]|object[175]	new[174]|giv[175]	_	_
24-29	3439-3447	aromatic	substance[174]|object[175]	new[174]|giv[175]	_	_
24-30	3448-3451	box	substance[174]|object[175]	new[174]|giv[175]	_	_
24-31	3452-3454	of	substance[174]|object[175]	new[174]|giv[175]	_	_
24-32	3455-3458	the	substance[174]|object[175]|place[178]	new[174]|giv[175]|giv[178]	coref	34-16[246_178]
24-33	3459-3464	nAChR	substance[174]|object[175]|abstract|place[178]	new[174]|giv[175]|giv|giv[178]	coref	34-17
24-34	3465-3476	orthosteric	substance[174]|object[175]|place[178]	new[174]|giv[175]|giv[178]	_	_
24-35	3477-3484	binding	substance[174]|object[175]|object|place[178]	new[174]|giv[175]|giv|giv[178]	_	_
24-36	3485-3489	site	substance[174]|object[175]|place[178]	new[174]|giv[175]|giv[178]	_	_
24-37	3490-3493	and	_	_	_	_
24-38	3494-3498	this	abstract	giv	coref	34-7[243_0]
24-39	3499-3502	may	_	_	_	_
24-40	3503-3505	be	_	_	_	_
24-41	3506-3519	energetically	_	_	_	_
24-42	3520-3531	unfavorable	_	_	_	_
24-43	3532-3533	.	_	_	_	_

#Text=While 2,3′-bipyridyl displayed only a marginal potency at vertebrate receptors that could be predicted from its pKa , it has been found to be quite paralytic to insects and crustaceans .
25-1	3534-3539	While	_	_	_	_
25-2	3540-3554	2,3′-bipyridyl	abstract	new	coref	28-5
25-3	3555-3564	displayed	_	_	_	_
25-4	3565-3569	only	abstract[181]	giv[181]	ana	25-16[0_181]
25-5	3570-3571	a	abstract[181]	giv[181]	_	_
25-6	3572-3580	marginal	abstract[181]	giv[181]	_	_
25-7	3581-3588	potency	abstract[181]	giv[181]	_	_
25-8	3589-3591	at	abstract[181]	giv[181]	_	_
25-9	3592-3602	vertebrate	abstract[181]|abstract[182]	giv[181]|new[182]	_	_
25-10	3603-3612	receptors	abstract[181]|abstract[182]	giv[181]|new[182]	_	_
25-11	3613-3617	that	abstract[181]	giv[181]	_	_
25-12	3618-3623	could	abstract[181]	giv[181]	_	_
25-13	3624-3626	be	abstract[181]	giv[181]	_	_
25-14	3627-3636	predicted	abstract[181]	giv[181]	_	_
25-15	3637-3641	from	abstract[181]	giv[181]	_	_
25-16	3642-3645	its	abstract[181]|abstract|abstract[184]	giv[181]|giv|new[184]	ana	25-19
25-17	3646-3649	pKa	abstract[181]|abstract[184]	giv[181]|new[184]	_	_
25-18	3650-3651	,	_	_	_	_
25-19	3652-3654	it	abstract	giv	_	_
25-20	3655-3658	has	_	_	_	_
25-21	3659-3663	been	_	_	_	_
25-22	3664-3669	found	_	_	_	_
25-23	3670-3672	to	_	_	_	_
25-24	3673-3675	be	_	_	_	_
25-25	3676-3681	quite	_	_	_	_
25-26	3682-3691	paralytic	_	_	_	_
25-27	3692-3694	to	_	_	_	_
25-28	3695-3702	insects	animal	new	_	_
25-29	3703-3706	and	_	_	_	_
25-30	3707-3718	crustaceans	animal	new	_	_
25-31	3719-3720	.	_	_	_	_

#Text=At least some arthropod nAChRs are known to not require a cationic ligand for activation , as shown by many studies with neonicotinoid insecticides such as imidachloprid .
26-1	3721-3723	At	substance[189]	giv[189]	coref	27-9[198_189]
26-2	3724-3729	least	substance[189]	giv[189]	_	_
26-3	3730-3734	some	substance[189]	giv[189]	_	_
26-4	3735-3744	arthropod	animal|substance[189]	new|giv[189]	coref	28-8
26-5	3745-3751	nAChRs	substance[189]	giv[189]	_	_
26-6	3752-3755	are	_	_	_	_
26-7	3756-3761	known	_	_	_	_
26-8	3762-3764	to	_	_	_	_
26-9	3765-3768	not	_	_	_	_
26-10	3769-3776	require	_	_	_	_
26-11	3777-3778	a	substance[190]	new[190]	_	_
26-12	3779-3787	cationic	substance[190]	new[190]	_	_
26-13	3788-3794	ligand	substance[190]	new[190]	_	_
26-14	3795-3798	for	_	_	_	_
26-15	3799-3809	activation	event	new	_	_
26-16	3810-3811	,	_	_	_	_
26-17	3812-3814	as	_	_	_	_
26-18	3815-3820	shown	_	_	_	_
26-19	3821-3823	by	_	_	_	_
26-20	3824-3828	many	abstract[192]	giv[192]	_	_
26-21	3829-3836	studies	abstract[192]	giv[192]	_	_
26-22	3837-3841	with	abstract[192]	giv[192]	_	_
26-23	3842-3855	neonicotinoid	abstract[192]|abstract|animal[194]	giv[192]|new|new[194]	_	_
26-24	3856-3868	insecticides	abstract[192]|animal[194]	giv[192]|new[194]	_	_
26-25	3869-3873	such	abstract[192]|animal[194]	giv[192]|new[194]	_	_
26-26	3874-3876	as	abstract[192]|animal[194]	giv[192]|new[194]	_	_
26-27	3877-3890	imidachloprid	abstract[192]|animal[194]|substance	giv[192]|new[194]|new	_	_
26-28	3891-3892	.	_	_	_	_

#Text=These neonicotinoids also display a limited activity at vertebrate nAChRs .
27-1	3893-3898	These	animal[196]	new[196]	_	_
27-2	3899-3913	neonicotinoids	animal[196]	new[196]	_	_
27-3	3914-3918	also	_	_	_	_
27-4	3919-3926	display	_	_	_	_
27-5	3927-3928	a	abstract[197]	giv[197]	ana	28-1[0_197]
27-6	3929-3936	limited	abstract[197]	giv[197]	_	_
27-7	3937-3945	activity	abstract[197]	giv[197]	_	_
27-8	3946-3948	at	_	_	_	_
27-9	3949-3959	vertebrate	substance[198]	giv[198]	coref	28-7[202_198]
27-10	3960-3966	nAChRs	substance[198]	giv[198]	_	_
27-11	3967-3968	.	_	_	_	_

#Text=It seems likely that 2,3′-bipyridyl affects some arthropod nAChRs through its unionized form .
28-1	3969-3971	It	abstract	giv	ana	28-11
28-2	3972-3977	seems	_	_	_	_
28-3	3978-3984	likely	_	_	_	_
28-4	3985-3989	that	_	_	_	_
28-5	3990-4004	2,3′-bipyridyl	abstract	giv	_	_
28-6	4005-4012	affects	_	_	_	_
28-7	4013-4017	some	substance[202]	giv[202]	_	_
28-8	4018-4027	arthropod	animal|substance[202]	giv|giv[202]	_	_
28-9	4028-4034	nAChRs	substance[202]	giv[202]	_	_
28-10	4035-4042	through	_	_	_	_
28-11	4043-4046	its	abstract|abstract[204]	giv|giv[204]	coref	34-28[249_204]
28-12	4047-4056	unionized	abstract[204]	giv[204]	_	_
28-13	4057-4061	form	abstract[204]	giv[204]	_	_
28-14	4062-4063	.	_	_	_	_

#Text=One can speculate as to what advantage(s) might accrue to an organism ( in this case , a hoplonemertine or ant ) to produce and secrete an imine-bond containing toxin like anabaseine .
29-1	4064-4067	One	person	giv	_	_
29-2	4068-4071	can	_	_	_	_
29-3	4072-4081	speculate	_	_	_	_
29-4	4082-4084	as	_	_	_	_
29-5	4085-4087	to	_	_	_	_
29-6	4088-4092	what	_	_	_	_
29-7	4093-4105	advantage(s)	abstract	new	_	_
29-8	4106-4111	might	_	_	_	_
29-9	4112-4118	accrue	_	_	_	_
29-10	4119-4121	to	_	_	_	_
29-11	4122-4124	an	animal[207]	new[207]	appos	29-15[210_207]
29-12	4125-4133	organism	animal[207]	new[207]	_	_
29-13	4134-4135	(	_	_	_	_
29-14	4136-4138	in	_	_	_	_
29-15	4139-4143	this	abstract[208]|plant[209]|animal[210]	new[208]|new[209]|giv[210]	appos	29-21[0_210]
29-16	4144-4148	case	abstract[208]|plant[209]|animal[210]	new[208]|new[209]|giv[210]	_	_
29-17	4149-4150	,	plant[209]|animal[210]	new[209]|giv[210]	_	_
29-18	4151-4152	a	plant[209]|animal[210]	new[209]|giv[210]	_	_
29-19	4153-4167	hoplonemertine	plant[209]|animal[210]	new[209]|giv[210]	_	_
29-20	4168-4170	or	animal[210]	giv[210]	_	_
29-21	4171-4174	ant	animal[210]|animal	giv[210]|giv	_	_
29-22	4175-4176	)	_	_	_	_
29-23	4177-4179	to	_	_	_	_
29-24	4180-4187	produce	_	_	_	_
29-25	4188-4191	and	_	_	_	_
29-26	4192-4199	secrete	_	_	_	_
29-27	4200-4202	an	substance[213]	new[213]	coref	36-3[268_213]
29-28	4203-4213	imine-bond	substance|substance[213]	new|new[213]	_	_
29-29	4214-4224	containing	substance[213]	new[213]	_	_
29-30	4225-4230	toxin	substance[213]	new[213]	_	_
29-31	4231-4235	like	substance[213]	new[213]	_	_
29-32	4236-4246	anabaseine	substance[213]|substance	new[213]|giv	coref	30-24
29-33	4247-4248	.	_	_	_	_

#Text=The entire body wall integument as well as the contiguous epithelium of the anterior proboscis of P. peregrina contains very high concentrations of anabaseine .
30-1	4249-4252	The	abstract[217]	new[217]	coref	32-15[235_217]
30-2	4253-4259	entire	abstract[217]	new[217]	_	_
30-3	4260-4264	body	object|place[216]|abstract[217]	new|new[216]|new[217]	_	_
30-4	4265-4269	wall	place[216]|abstract[217]	new[216]|new[217]	_	_
30-5	4270-4280	integument	abstract[217]	new[217]	_	_
30-6	4281-4283	as	_	_	_	_
30-7	4284-4288	well	_	_	_	_
30-8	4289-4291	as	_	_	_	_
30-9	4292-4295	the	place[218]	new[218]	coref	31-16[228_218]
30-10	4296-4306	contiguous	place[218]	new[218]	_	_
30-11	4307-4317	epithelium	place[218]	new[218]	_	_
30-12	4318-4320	of	place[218]	new[218]	_	_
30-13	4321-4324	the	place[218]|object[219]	new[218]|new[219]	coref	31-1[223_219]
30-14	4325-4333	anterior	place[218]|object[219]	new[218]|new[219]	_	_
30-15	4334-4343	proboscis	place[218]|object[219]	new[218]|new[219]	_	_
30-16	4344-4346	of	place[218]|object[219]	new[218]|new[219]	_	_
30-17	4347-4349	P.	place[218]|object[219]|animal[220]	new[218]|new[219]|new[220]	_	_
30-18	4350-4359	peregrina	place[218]|object[219]|animal[220]	new[218]|new[219]|new[220]	_	_
30-19	4360-4368	contains	_	_	_	_
30-20	4369-4373	very	abstract[221]	giv[221]	_	_
30-21	4374-4378	high	abstract[221]	giv[221]	_	_
30-22	4379-4393	concentrations	abstract[221]	giv[221]	_	_
30-23	4394-4396	of	abstract[221]	giv[221]	_	_
30-24	4397-4407	anabaseine	abstract[221]|substance	giv[221]|giv	coref	33-14
30-25	4408-4409	.	_	_	_	_

#Text=The proboscis everts and wraps around the prey during its capture allowing extensive contact of this epithelium with its annelid prey .
31-1	4410-4413	The	object[223]	giv[223]	coref	32-5[232_223]
31-2	4414-4423	proboscis	object[223]	giv[223]	_	_
31-3	4424-4430	everts	_	_	_	_
31-4	4431-4434	and	_	_	_	_
31-5	4435-4440	wraps	_	_	_	_
31-6	4441-4447	around	_	_	_	_
31-7	4448-4451	the	animal[224]	new[224]	ana	31-10[0_224]
31-8	4452-4456	prey	animal[224]	new[224]	_	_
31-9	4457-4463	during	_	_	_	_
31-10	4464-4467	its	animal|event[226]	giv|new[226]	ana	31-19
31-11	4468-4475	capture	event[226]	new[226]	_	_
31-12	4476-4484	allowing	event[226]	new[226]	_	_
31-13	4485-4494	extensive	event[226]|event[227]	new[226]|new[227]	_	_
31-14	4495-4502	contact	event[226]|event[227]	new[226]|new[227]	_	_
31-15	4503-4505	of	event[226]|event[227]	new[226]|new[227]	_	_
31-16	4506-4510	this	event[226]|event[227]|place[228]	new[226]|new[227]|giv[228]	_	_
31-17	4511-4521	epithelium	event[226]|event[227]|place[228]	new[226]|new[227]|giv[228]	_	_
31-18	4522-4526	with	event[226]|event[227]	new[226]|new[227]	_	_
31-19	4527-4530	its	event[226]|event[227]|animal|animal[230]	new[226]|new[227]|giv|giv[230]	coref|coref	31-19[230_0]|32-16[0_230]
31-20	4531-4538	annelid	event[226]|event[227]|animal[230]	new[226]|new[227]|giv[230]	_	_
31-21	4539-4543	prey	event[226]|event[227]|animal[230]	new[226]|new[227]|giv[230]	_	_
31-22	4544-4545	.	_	_	_	_

#Text=The mineralized stylet of the proboscis can be observed to produce multiple punctures of the prey integument , which should further facilitate envenomation .
32-1	4546-4549	The	abstract[231]	new[231]	_	_
32-2	4550-4561	mineralized	abstract[231]	new[231]	_	_
32-3	4562-4568	stylet	abstract[231]	new[231]	_	_
32-4	4569-4571	of	abstract[231]	new[231]	_	_
32-5	4572-4575	the	abstract[231]|object[232]	new[231]|giv[232]	_	_
32-6	4576-4585	proboscis	abstract[231]|object[232]	new[231]|giv[232]	_	_
32-7	4586-4589	can	_	_	_	_
32-8	4590-4592	be	_	_	_	_
32-9	4593-4601	observed	_	_	_	_
32-10	4602-4604	to	_	_	_	_
32-11	4605-4612	produce	_	_	_	_
32-12	4613-4621	multiple	object[233]	new[233]	_	_
32-13	4622-4631	punctures	object[233]	new[233]	_	_
32-14	4632-4634	of	object[233]	new[233]	_	_
32-15	4635-4638	the	object[233]|abstract[235]	new[233]|giv[235]	coref	34-52[255_235]
32-16	4639-4643	prey	object[233]|animal|abstract[235]	new[233]|giv|giv[235]	coref	34-55[256_0]
32-17	4644-4654	integument	object[233]|abstract[235]	new[233]|giv[235]	_	_
32-18	4655-4656	,	object[233]	new[233]	_	_
32-19	4657-4662	which	object[233]	new[233]	_	_
32-20	4663-4669	should	object[233]	new[233]	_	_
32-21	4670-4677	further	object[233]	new[233]	_	_
32-22	4678-4688	facilitate	object[233]	new[233]	_	_
32-23	4689-4701	envenomation	object[233]|event	new[233]|new	_	_
32-24	4702-4703	.	_	_	_	_

#Text=In addition , potential predators will also be exposed in these ways to anabaseine and related alkaloids .
33-1	4704-4706	In	_	_	_	_
33-2	4707-4715	addition	_	_	_	_
33-3	4716-4717	,	_	_	_	_
33-4	4718-4727	potential	animal[237]	new[237]	_	_
33-5	4728-4737	predators	animal[237]	new[237]	_	_
33-6	4738-4742	will	_	_	_	_
33-7	4743-4747	also	_	_	_	_
33-8	4748-4750	be	_	_	_	_
33-9	4751-4758	exposed	_	_	_	_
33-10	4759-4761	in	_	_	_	_
33-11	4762-4767	these	abstract[238]	new[238]	_	_
33-12	4768-4772	ways	abstract[238]	new[238]	_	_
33-13	4773-4775	to	_	_	_	_
33-14	4776-4786	anabaseine	substance	giv	coref	35-27
33-15	4787-4790	and	_	_	_	_
33-16	4791-4798	related	substance[240]	new[240]	_	_
33-17	4799-4808	alkaloids	substance[240]	new[240]	_	_
33-18	4809-4810	.	_	_	_	_

#Text=Perhaps a major advantage of possessing an imine bond , besides an enhanced affinity for the nAChR orthosteric site , is its low basicity , which allows the unionized form to reach a relatively high concentration in the neutral pH range of the marine environment and thereby enhance passive diffusion across the integument of the prey or predator .
34-1	4811-4818	Perhaps	_	_	_	_
34-2	4819-4820	a	abstract[241]	new[241]	coref	34-22[248_241]
34-3	4821-4826	major	abstract[241]	new[241]	_	_
34-4	4827-4836	advantage	abstract[241]	new[241]	_	_
34-5	4837-4839	of	abstract[241]	new[241]	_	_
34-6	4840-4850	possessing	abstract[241]	new[241]	_	_
34-7	4851-4853	an	abstract[241]|abstract[243]	new[241]|giv[243]	_	_
34-8	4854-4859	imine	abstract[241]|substance|abstract[243]	new[241]|new|giv[243]	_	_
34-9	4860-4864	bond	abstract[241]|abstract[243]	new[241]|giv[243]	_	_
34-10	4865-4866	,	abstract[241]	new[241]	_	_
34-11	4867-4874	besides	abstract[241]	new[241]	_	_
34-12	4875-4877	an	abstract[241]|abstract[244]	new[241]|new[244]	ana	34-22[0_244]
34-13	4878-4886	enhanced	abstract[241]|abstract[244]	new[241]|new[244]	_	_
34-14	4887-4895	affinity	abstract[241]|abstract[244]	new[241]|new[244]	_	_
34-15	4896-4899	for	abstract[241]|abstract[244]	new[241]|new[244]	_	_
34-16	4900-4903	the	abstract[241]|abstract[244]|place[246]	new[241]|new[244]|giv[246]	_	_
34-17	4904-4909	nAChR	abstract[241]|abstract[244]|abstract|place[246]	new[241]|new[244]|giv|giv[246]	_	_
34-18	4910-4921	orthosteric	abstract[241]|abstract[244]|place[246]	new[241]|new[244]|giv[246]	_	_
34-19	4922-4926	site	abstract[241]|abstract[244]|place[246]	new[241]|new[244]|giv[246]	_	_
34-20	4927-4928	,	_	_	_	_
34-21	4929-4931	is	_	_	_	_
34-22	4932-4935	its	abstract|abstract[248]	giv|giv[248]	_	_
34-23	4936-4939	low	abstract[248]	giv[248]	_	_
34-24	4940-4948	basicity	abstract[248]	giv[248]	_	_
34-25	4949-4950	,	abstract[248]	giv[248]	_	_
34-26	4951-4956	which	abstract[248]	giv[248]	_	_
34-27	4957-4963	allows	abstract[248]	giv[248]	_	_
34-28	4964-4967	the	abstract[248]|abstract[249]	giv[248]|giv[249]	_	_
34-29	4968-4977	unionized	abstract[248]|abstract[249]	giv[248]|giv[249]	_	_
34-30	4978-4982	form	abstract[248]|abstract[249]	giv[248]|giv[249]	_	_
34-31	4983-4985	to	abstract[248]	giv[248]	_	_
34-32	4986-4991	reach	abstract[248]	giv[248]	_	_
34-33	4992-4993	a	abstract[248]|abstract[250]	giv[248]|giv[250]	_	_
34-34	4994-5004	relatively	abstract[248]|abstract[250]	giv[248]|giv[250]	_	_
34-35	5005-5009	high	abstract[248]|abstract[250]	giv[248]|giv[250]	_	_
34-36	5010-5023	concentration	abstract[248]|abstract[250]	giv[248]|giv[250]	_	_
34-37	5024-5026	in	abstract[248]	giv[248]	_	_
34-38	5027-5030	the	abstract[248]|abstract[252]	giv[248]|new[252]	coref	35-20[266_252]
34-39	5031-5038	neutral	abstract[248]|abstract[252]	giv[248]|new[252]	_	_
34-40	5039-5041	pH	abstract[248]|substance|abstract[252]	giv[248]|new|new[252]	coref	35-15[263_0]
34-41	5042-5047	range	abstract[248]|abstract[252]	giv[248]|new[252]	_	_
34-42	5048-5050	of	abstract[248]|abstract[252]	giv[248]|new[252]	_	_
34-43	5051-5054	the	abstract[248]|abstract[252]|place[253]	giv[248]|new[252]|new[253]	_	_
34-44	5055-5061	marine	abstract[248]|abstract[252]|place[253]	giv[248]|new[252]|new[253]	_	_
34-45	5062-5073	environment	abstract[248]|abstract[252]|place[253]	giv[248]|new[252]|new[253]	_	_
34-46	5074-5077	and	abstract[248]	giv[248]	_	_
34-47	5078-5085	thereby	abstract[248]	giv[248]	_	_
34-48	5086-5093	enhance	abstract[248]	giv[248]	_	_
34-49	5094-5101	passive	abstract[248]|abstract[254]	giv[248]|new[254]	_	_
34-50	5102-5111	diffusion	abstract[248]|abstract[254]	giv[248]|new[254]	_	_
34-51	5112-5118	across	_	_	_	_
34-52	5119-5122	the	abstract[255]	giv[255]	_	_
34-53	5123-5133	integument	abstract[255]	giv[255]	_	_
34-54	5134-5136	of	abstract[255]	giv[255]	_	_
34-55	5137-5140	the	abstract[255]|animal[256]	giv[255]|giv[256]	_	_
34-56	5141-5145	prey	abstract[255]|animal[256]	giv[255]|giv[256]	_	_
34-57	5146-5148	or	abstract[255]	giv[255]	_	_
34-58	5149-5157	predator	abstract[255]|animal	giv[255]|new	_	_
34-59	5158-5159	.	_	_	_	_

#Text=The integument of a marine organism exposed to sea water is likely to have a pH near 8 , well above the pH range in which anabaseine is primarily ionized .
35-1	5160-5163	The	abstract[258]	new[258]	_	_
35-2	5164-5174	integument	abstract[258]	new[258]	_	_
35-3	5175-5177	of	abstract[258]	new[258]	_	_
35-4	5178-5179	a	abstract[258]|animal[260]	new[258]|new[260]	_	_
35-5	5180-5186	marine	abstract[258]|organization|animal[260]	new[258]|new|new[260]	_	_
35-6	5187-5195	organism	abstract[258]|animal[260]	new[258]|new[260]	_	_
35-7	5196-5203	exposed	abstract[258]|animal[260]	new[258]|new[260]	_	_
35-8	5204-5206	to	abstract[258]|animal[260]	new[258]|new[260]	_	_
35-9	5207-5210	sea	abstract[258]|animal[260]|place|substance[262]	new[258]|new[260]|new|new[262]	_	_
35-10	5211-5216	water	abstract[258]|animal[260]|substance[262]	new[258]|new[260]|new[262]	_	_
35-11	5217-5219	is	_	_	_	_
35-12	5220-5226	likely	_	_	_	_
35-13	5227-5229	to	_	_	_	_
35-14	5230-5234	have	_	_	_	_
35-15	5235-5236	a	substance[263]	giv[263]	coref	35-23[0_263]
35-16	5237-5239	pH	substance[263]	giv[263]	_	_
35-17	5240-5244	near	substance[263]	giv[263]	_	_
35-18	5245-5246	8	substance[263]|abstract	giv[263]|new	_	_
35-19	5247-5248	,	_	_	_	_
35-20	5249-5253	well	abstract[266]	giv[266]	_	_
35-21	5254-5259	above	abstract[266]	giv[266]	_	_
35-22	5260-5263	the	abstract[266]	giv[266]	_	_
35-23	5264-5266	pH	substance|abstract[266]	giv|giv[266]	_	_
35-24	5267-5272	range	abstract[266]	giv[266]	_	_
35-25	5273-5275	in	abstract[266]	giv[266]	_	_
35-26	5276-5281	which	abstract[266]	giv[266]	_	_
35-27	5282-5292	anabaseine	abstract[266]|substance	giv[266]|giv	coref	36-16
35-28	5293-5295	is	abstract[266]	giv[266]	_	_
35-29	5296-5305	primarily	abstract[266]	giv[266]	_	_
35-30	5306-5313	ionized	abstract[266]	giv[266]	_	_
35-31	5314-5315	.	_	_	_	_

#Text=Thus , the toxin has a much better chance of entering the prey/predator than would anabaseine , the more basic secondary amine analog of anabaseine .
36-1	5316-5320	Thus	_	_	_	_
36-2	5321-5322	,	_	_	_	_
36-3	5323-5326	the	substance[268]	giv[268]	_	_
36-4	5327-5332	toxin	substance[268]	giv[268]	_	_
36-5	5333-5336	has	_	_	_	_
36-6	5337-5338	a	abstract[269]	new[269]	_	_
36-7	5339-5343	much	abstract[269]	new[269]	_	_
36-8	5344-5350	better	abstract[269]	new[269]	_	_
36-9	5351-5357	chance	abstract[269]	new[269]	_	_
36-10	5358-5360	of	abstract[269]	new[269]	_	_
36-11	5361-5369	entering	abstract[269]	new[269]	_	_
36-12	5370-5373	the	abstract[269]|animal[270]	new[269]|new[270]	_	_
36-13	5374-5387	prey/predator	abstract[269]|animal[270]	new[269]|new[270]	_	_
36-14	5388-5392	than	abstract[269]	new[269]	_	_
36-15	5393-5398	would	abstract[269]	new[269]	_	_
36-16	5399-5409	anabaseine	abstract[269]|substance	new[269]|giv	appos	36-18[273_0]
36-17	5410-5411	,	_	_	_	_
36-18	5412-5415	the	substance[273]	giv[273]	coref	36-25[0_273]
36-19	5416-5420	more	substance[273]	giv[273]	_	_
36-20	5421-5426	basic	substance[273]	giv[273]	_	_
36-21	5427-5436	secondary	substance[272]|substance[273]	new[272]|giv[273]	_	_
36-22	5437-5442	amine	substance[272]|substance[273]	new[272]|giv[273]	_	_
36-23	5443-5449	analog	substance[273]	giv[273]	_	_
36-24	5450-5452	of	substance[273]	giv[273]	_	_
36-25	5453-5463	anabaseine	substance[273]|substance	giv[273]|giv	_	_
36-26	5464-5465	.	_	_	_	_
